Patrick Higgins, MD
Ophthalmology · Bloomfield, NJNPI 1285642470
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,299 of the $7,726 with a category attached, or 68.6%. 32 manufacturers reported payments, led by Roche TCRC, Inc. at 31.5% of the total.
Across 116 payments — averaging $66.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$2K
- Ocular Therapeutix, Inc.$700
- Regeneron Healthcare Solutions, Inc.$488
- Genentech USA, Inc.$460
- AbbVie$449
- Apellis Pharmaceuticals, Inc.$417
- plus $3K from 26 others
Across 961 payments — averaging $17,453 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$9.3M
- Novartis$4.4M
- Bayer$1M
- Ocular Therapeutix, Inc.$637K
- Regeneron$321K
- Boehringer Ingelheim$310K
- plus $836K from 10 others
What the payments were for
- Speaking & faculty fees$100%
- Travel & lodging$2,28530%
- Food & beverage$5,29969%
- Education$1131%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 2 | $2,437 |
| Ocular Therapeutix, Inc. | 6 | $700 |
| Regeneron Healthcare Solutions, Inc. | 5 | $488 |
| Genentech USA, Inc. | 10 | $460 |
| AbbVie(2 entities) | 20 | $449 |
| Apellis Pharmaceuticals, Inc. | 8 | $417 |
| Glaukos Corporation | 3 | $397 |
| Sun Pharmaceutical Industries Inc. | 4 | $257 |
| Alimera Sciences, Inc. | 15 | $243 |
| Tarsus Pharmaceuticals, Inc. | 2 | $216 |
| Biotissue Holdings Inc. | 3 | $208 |
| Alcon | 3 | $196 |
| Coherus Oncology, Inc. | 2 | $195 |
| Rxsight Inc | 2 | $158 |
| Sight Sciences, Inc. | 2 | $121 |
| Bausch & Lomb Americas Inc. | 1 | $114 |
| Astellas Pharma US Inc | 5 | $109 |
| Dompe US, Inc. | 1 | $108 |
| Novartis | 5 | $81 |
| Harrow Eye, LLC | 2 | $77 |
| ANI Pharmaceuticals, Inc. | 4 | $75 |
| Eyepoint US, Inc. | 1 | $64 |
| Johnson & Johnson | 1 | $24 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Spark Therapeutics, Inc. | 1 | $13 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Notal Vision, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$2,437
- DEXTENZA$540
- iDoseTR$303
- VABYSMO$269
- EYLEA HD$255
- CEQUA$228
- enVista MX60 IOL$227
- XDEMVY$216
- iStent Infinite$192
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$126
- Cimerli$125
- EYLEA$124
- DURYSTA$113
- Oxervate$108
- AmnioGraft$107
- OMNI(R) SURGICAL SYSTEM (US)$101
- SION SURGICAL INSTRUMENT$101
How this compares
$7,726 in reported general payments places this provider in the 85th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 49 | $16,728 |
| Prednisolone Acetate | 271 | $13,473 |
| LumiganBimatoprost | 32 | $11,812 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $7,216 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 41 | $6,640 |
| Bromfenac Sodium | 31 | $6,501 |
| Loteprednol Etabonate | 31 | $5,898 |
| Ketorolac Tromethamine | 109 | $3,607 |
| Brimonidine Tartrate | 44 | $2,724 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 110 | $1,522 |
| Latanoprost | 163 | $1,300 |
| Atropine Sulfate | 27 | $1,159 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 114 | $766 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $500 |
| Acetazolamide | 13 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $13 | $22,62680 claims |
| AbbVieLumigan, Combigan | $449 | $19,02856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Bloomfield
- Devang BhoiwalaBloomfield$12K
- Lauren AngiolettiBloomfield$8K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.